Médicaments en développement en 2009 pour les cancers « tête et cou » (InTextoResearch)
SciMedWeb
● Abraxane (albumin-bound paclitaxel) Phase I/II
● Advexin (contusugene ladenovec) Phase III
● Alimta (pemetrexed) Phase III
● AP-5346 Phase II
● ARQ-501 (beta lapachone) Phase II
● Avastin (bevacizumab) Phase III
● BIBW 2992 Phase II
● bleomycin (electrical pulse delivery) Phase III
● Erbitux (cetuximab)
● eribulin mesylate (E7389) Phase II
● Gemzar (gemcitabine) Phase I
● Hycamtin (topotecan) Phase II
● IMC-A12 Phase II
● ING 234 (mouthwash) Phase II
● INGN 241 (mda-7) Phase III
● IRX-2 Phase II
● Multikine (leukocyte interleukin) Phase II
● OBP-301 Phase I
● perifosine Phase II
● Reolysin (reovirus) Phase II
● SCH-58500 (p53 gene therapy) Phase I
● sibrotuzumab Phase II
● Tarceva (erlotinib) Phase III
● TAS-106 Phase II
● tegafur/uracil combination Phase II
● terameprocol Phase I
● Thymitaq (nolatrexed) hase II
● TNFerade Phase I/II
● Tykerb (lapatinib) Phase III
● VB-4845 Phase II
● Vectibix (panitumumab) Phase III
● XL-880 Phase II
● zalutumumab Phase II
● Zybrestat (fosbretabulin) Phase I/II
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)